The World Health Organization has prequalified Coartem Baby, Novartis’ antimalarial combination medicine for infants. Novartis developed the product in partnership with Medicines for Malaria Venture (MMV), making the WHO’s review a key regulatory gateway for wider procurement. Prequalification supports eligible countries and procurement agencies to use the regimen in public health programs, which can accelerate supply and uptake where infant malaria treatment is a persistent challenge. The news positions Coartem Baby as the first and only WHO-prequalified antimalarial for babies referenced in the reporting.